Great Work — Utah

Official Website: Atavistik Bio

source confidence: Medium status: Useful updated 2026-06-19

Type
source
Status
Useful
Confidence
Medium
Source Type
official-page
URL
https://atavistikbio.com
Archive
https://web.archive.org/web/20260423004100/https://atavistikbio.com/
Archived
2026-04-23
Publisher
Atavistik Bio
Raw
raw/atavistik-bio-official-website/2026-08-11-d25431bf4cc6.txt
Retrieved
2026-08-12
Updated
2026-06-19

Summary

Atavistik Bio's official website describes a clinical-stage biotechnology company developing selective allosteric small-molecule therapeutics. The site positions the company's approach as enabling modulation of disease-causing proteins through non-active-site regulatory pockets, with pipeline programs in hereditary hemorrhagic telangiectasia (HHT), myeloproliferative neoplasms (MPNs), and additional discovery-stage assets.

Useful Claims

  • Atavistik Bio is a clinical-stage biotech developing novel allosteric therapeutics with potential for transformative treatment in serious diseases.
  • Lead asset ATV-1601 is described as an oral, allosteric AKT1-selective inhibitor advancing for hereditary hemorrhagic telangiectasia (HHT).
  • A JAK2 V617F mutant-selective inhibitor program is listed for myeloproliferative neoplasms (MPNs).
  • Recent company news on the captured home page reports U.S. FDA clearance of an IND plus Fast Track designation for ATV-1601 in HHT in June 2026.
  • The company invites candidates to join an "experienced and innovative team" through a careers page.

Open Questions

  • The previously reported $120M Series B and $40M extension ($160M total) are absent from this capture and remain unverified here.

Verbatim

"Atavistik Bio is a clinical stage biotechnology company developing novel allosteric therapeutics." — Home page, company description

"We are advancing multiple programs with best-in-class potential, including our lead asset, ATV-1601, an oral allosteric AKT1-selective inhibitor for the treatment of Hereditary Hemorrhagic Telangiectasia (HHT) and advancing a JAK2 V617F mutant-selective inhibitor program for myeloproliferative neoplasms." — Home page, pipeline

"Atavistik Bio Announces U.S. FDA Clearance of Investigational New Drug Application and Fast Track Designation for ATV-1601 for the Treatment of Hereditary Hemorrhagic Telangiectasia (HHT)" — Home page, June 9, 2026 news listing

Reliability Notes

The capture does not show the December 2025 $120M Series B or March 2026 $40M extension; those financing claims require the underlying press releases.

This is an official company source. It is useful for pipeline positioning, financing announcements, and regulatory milestones, but clinical efficacy, competitive differentiation, and platform breadth should be cross-checked with SEC filings (if/when public), peer-reviewed publications, clinical trial registries, and independent biotech reporting. Pipeline emphasis on HHT in 2026 site copy may reflect program reprioritization relative to earlier public descriptions focused on AKT1 E17K solid tumors.

Related Pages

See Also